🟢 Anixa Biosciences is trading 5.19% up today after positive breast-cancer vaccine Phase 1 data

Anixa Biosciences is trading 5.19% up at $2.73 after positive breast-cancer vaccine Phase 1 data.

• The company is advancing its breast-cancer vaccine toward Phase 2.
• It is continuing its ovarian-cancer CAR-T Phase 1 trial, with encouraging survival observations.
• Dr. Carmen Guerra was appointed to its Cancer Business Advisory Board on September 16, 2026; the appointment and clinical updates provide a clear company-specific catalyst.